Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KH658 Gene Therapy for Neovascular AMD
NCT06458595Phase 2Recruiting
- Sponsor
- Chengdu Origen Biotechnology Co., Ltd.
- Start
- Jun 2024
- Primary completion
- Mar 2026
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KH658 in neovascular age-related macular degeneration (NVAMD), sponsored by Chengdu Origen Biotechnology Co., Ltd. Primary endpoints: Tolerability and safety of KH658 at Week 26 and Change in Best Corrected Visual Acuity letter score at Week 26. Started Jun 2024; status: recruiting.
02
Drugs
KH658
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT06458595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06458595.